Lilly Shifts Gears In China With New Shanghai-based R&D Center
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly is deepening its commitment to China and diabetics in the country by opening a new R&D center in Shanghai that aims to discover novel compounds that will lead to breakthrough therapies for diabetes
You may also be interested in...
An Asia Hub: Novartis Plans Biotech Manufacturing Center In Singapore
Novartis plans to build a new center of excellence for biotechnology manufacturing costing more than $500 million, as it looks to leverage Singapore’s skilled labor force and proximity to growth markets like China.
Lilly Diabetes R&D Center Arms Firm For Battle In China
Lilly’s first R&D center in China will focus on developing therapies that target the genetic profile and dietary habits of Asian diabetes patients.
New Diabetes R&D Center Arms Eli Lilly For Battle In China
Lilly’s first R&D center in China will focus on developing therapies that target the genetic profile and dietary habits of Asian diabetes patients.